

[ABSTRACTS SELECTED FOR POSTER PRESENTATIONS](#)

[Adjuvant Colon Cancer](#)

abstr 0943

Retrospective Assessment of an Alternative Adjuvant Treatment of Colon Cancer: Oxaliplatin Plus Weekly Bolus 5-Fluorouracil/ Leucovorin

Esther Uña Cidón¹, Francisco López-Lara²

¹Medical Oncology Service, ²Radiotherapy Oncology Service
Clinical University Hospital, Valladolid, Spain

Purpose: Oxaliplatin and 5-fluorouracil (5-FU) are the most widely used chemotherapeutic agents in the adjuvant treatment of colon cancer. It is known that the addition of oxaliplatin to weekly 5-FU and leucovorin chemotherapy significantly improves disease-free survival (DFS) in patients with stage II and III colon cancer. This study reviews the efficacy and toxicity of this regimen in our institution.

Patients and Methods: Patients with stage III colon cancer who had undergone a potentially curative resection were identified and their clinical histories reviewed. Treatment had consisted of 5-FU 425 mg/m² given weekly by intravenous (IV) bolus injection for 4 weeks plus leucovorin 20 mg/m² IV weekly for 4 weeks during each 4-week cycle for six cycles, with oxaliplatin 85 mg/m² IV administered on days 1, 15, and 29 of each 4-week cycle.

Results: A total of 28 patients were eligible for the assessment, including 16 males and 12 females. Median age was 53 years (32 – 66 years). Median follow-up for patients still alive has been 32 months. The 2-year DFS rate was 78%. Rates of grade 3 toxicities were thrombocytopenia in 6.7%, neurosensory effects in 7.7%, diarrhea in 4.2%, and asthenia in 3% of patients. None of the patients died from toxicity-related effects. Dose reduction by one level (ie, 25%) was performed for oxaliplatin in 5% of patients, and for 5-FU in 7% of patients.

Conclusion: Toxicities were generally manageable and DFS was similar to that achieved with other oxaliplatin/5-FU regimens. Therefore, this regimen could be an option in colon cancer patients undergoing radical resection who refuse oral therapies and continuous infusion of 5-FU.